Connexus Therapeutics is a private, venture-backed biotechnology startup.
Connexus Therapeutics has raised $5.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Connexus Therapeutics's investors include Lilly Asia Ventures, OrbiMed, Biokin Pharmaceutical, HitGen.
Connexus Therapeutics is headquartered in Hong Kong, Hong Kong.
Connexus Therapeutics is a private, venture-backed biotechnology startup.
Connexus Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Connexus Therapeutics — Funding & Investors." VCBacked, September 17, 2026, https://www.vcbacked.co/company/connexus-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). Connexus Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/connexus-therapeutics
{{cite web |title=Connexus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/connexus-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated